| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5954826 | Chest | 2014 | 7 Pages |
Abstract
Current guidelines for macrolide/azalide-based therapies for NB MAC lung disease result in favorable microbiologic outcomes for most patients without promotion of macrolide resistance. Intermittent therapy is effective and significantly better tolerated than daily therapy. Microbiologic recurrences during or after therapy are common and most often due to reinfection MAC genotypes.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Richard J. MD, FCCP, Barbara A. MS, Steven BS, Julie V. MD, Jessica BS, Rebecca W. BS, Deanna S. RN, Sara MS, David E. MD, FCCP,